Mr. Bloom's practice is focused on the representation of emerging and public life science companies, and he serves as principal outside or general counsel to leading life science companies. In addition to day-to-day corporate counseling and strategic advice to his clients, he regularly handles a variety of major business transactions, including public offerings, mergers and acquisitions, venture capital financings and strategic commercial transactions.
Mr. Bloom’s representative clients include, among others: 5AM Ventures; Akero Therapeutics; Alkermes; Alnylam Pharmaceuticals; Aptinyx; Assembly Biosciences; Atlas Venture; BeiGene; Black Diamond Therapeutics; BridgeBio; Cabaletta; Century Therapeutics; Cullinan Oncology; ElevateBio; Esperion Therapeutics; Fusion Pharmaceuticals; Gemini Therapeutics; Global Blood Therapeutics; iTeos Therapeutics; Karuna Therapeutics; MPM Capital; MyoKardia; Neon Therapeutics; Nimbus Therapeutics; ProQR Therapeutics; PureTech Health; Relay Therapeutics; resTORbio; Rheos Medicines; Sage Therapeutics; Tango Therapeutics; TCR2 Therapeutics; Third Rock Ventures; Vericel Corporation; Versant Ventures and Zafgen.
Representative Transactions
His recent client representations include work with:
- Ablynx NV in its $200 million initial public offering and €3.9 billion sale to Sanofi
- Accent Therapeutics in its $63 million Series B financing
- Achilles Therapeutics in its $120 million Series B financing
- AlloVir in its $317 million initial public offering and $120 million Series B financing
- Alnylam Pharmaceuticals in its $450 million and $805 million follow-on public offerings
- Alnylam Pharmaceuticals in its strategic alliance and $700 million equity financing with Genzyme
- Akero Therapeutics in its $216 million follow-on public offering and $106 million initial public offering
- Aptinyx in its $118 million initial public offering, $65 million Series A financing and $70 million Series B financing
- Arvelle Therapeutics in its licensing agreement with SK Biopharmaceuticals valued up to $530 million
- Assembly Biosciences in its $69 million public follow-on offering
- BeiGene in its $2.08 billion registered direct offering
- BeiGene in its $800 million and $200 million follow on public offerings and $158 million initial public offering
- BeiGene in its equity issuance in connection with its strategic oncology collaboration with Amgen
- Black Diamond Therapeutics in its $231.3 million initial public offering
- BridgeBio in its $348 million initial public offering and $300 million Series D Financing
- BridgeBio in its $550 million 144A offering
- Cabaletta Bio in its $74 million initial public offering and $50 million Series B financing
- Celyad in its $100 million initial public offering
- Century Therapeutics in its $250 million financing
- Checkmate Pharmaceuticals in its $75 million initial public offering
- COMPASS Pathfinder Holdings Limited in its $80 million Series B financing
- CRISPR Therapeutics in its joint venture with Bayer valued up to $335 million, $38 million additional Series B financing, $56 million initial public offering and $130 million follow-on offering
- Cullinan Oncology in its $150 million Series A financing
- DBV Technologies in its $92 million initial public offering
- Eidos Therapeutics in its $122 million initial public offering
- ElevateBio in its $150 million Series A financing
- Esperion Therapeutics in its $70 million initial public offering and subsequent $97 million and $201 million follow-on public offerings
- Fusion Pharmaceuticals in its $212.5 million initial public offering
- Galapagos in its $337 million follow-on public offering and $275 million initial public offering
- Galapagos in its strategic collaboration with Gilead Sciences valued up to $2 billion
- Global Blood Therapeutics in its $200 million, $100 million, $125 million and $120 million follow-on public offerings and $120 million initial public offering
- Gotham Therapeutics in its Series A financing
- HotSpot Therapeutics in its Series A financing
- Immatics in its $993 million business combination with Arya Sciences Acquisition Corp. and Nasdaq listing
- Inotek Pharmaceuticals in its $50 million and $69 million follow-on public offerings and $60 million initial public offering
- Inoteck Pharmaceuticals in its merger with Rocket Pharmaceuticals
- iTeos Therapeutics in its $201 million initial public offering and $125.3 million Series B financing
- Jounce Therapeutics in its $104 million initial public offering, $56 million Series B and $47 million Series A financings
- Karuna Therapeutics in its $250 million follow-on public offering and $103 million initial public offering
- Magenta Therapeutics in its $100 million initial public offering, $50 million Series B and Series A financings
- Maze Therapeutics in its $191 million Series financing
- MBX Biosciences in its $35 million Series A financing
- Mevion Medical Systems in connection with its $55 million equity and debt financing
- MyoKardia in its $604 million, $251 million, $143 million follow-on public offerings, $54 million initial public offering, and $46 million Series B financing
- Neon Therapeutics in its $100 million initial public offering, $70 million Series B financing and $55 million of Series A financing
- Neon Therapeutics in its $97 million all-stock sale to BioNTech
- Neos Therapeutics in its $75 million initial public offering
- Nimbus Therapeutics in its sale of Nimbus Apollo to Gilead Sciences valued up to $1.2 billion, collaborations with Monsanto and Shire Plc and its $43 million Series B financing
- Ocata Therapeutics in its $379 million sale to Astellas Pharma
- Orchard Therapeutics in its $225 million initial public offering
- ProQR Therapeutics in its $97.5 million initial public offering and $29 million public follow-on offering
- Proteostasis Therapeutics in its $50 million initial public offering, $65 million and $40 million follow-on public offerings
- Quartet Medicines in its $595 million strategic collaboration with Merck
- RA Capital and Versant Ventures in their investment in the $78 million Series A financing of T-knife
- RainDance Technologies in its sale to Bio-Rad Laboratories
- Relay Therapeutics in its $460 initial public offering, $400 million Series C financing, $63 million Series B financing and $57 million Series A financing
- resTORbio in its $85 million initial public offering
- resTORbio in its definitive merger agreement with Adicet Bio to create a combined publicly-traded biotechnology company
- Rheos Medicines in its $60 million Series A financing
- ROME Therapeutics in its launch and $50 million Series A financing
- Sage Therapeutics in its $90 million initial public offering and $138 million, $150 million, $175 million, $345 million and $575 million follow-on public offerings
- Tango Therapeutics in its $60 million Series B financing and $55 million Series A financing
- TCR2 Therapeutics in its $124 million follow on public offering, $75 million initial public offering, $125 million Series B financing, and $44.5 million Series A financing
- Voyager Therapeutics in its strategic collaboration with Genzyme for $100 million upfront and up to $745 million in milestone payments, and in its $45 million Series A financing, $60 million Series B financing and $70 million initial public offering
- Warp Drive Bio in its sale to Revolution Medicines
- Warp Drive Bio in its innovative strategic partnership with Sanofi
- Xeris Pharmaceuticals in its $98 million initial public offering
- Zafgen in its $137 million follow-on public offering and $96 million initial public offering
- Zafgen in its reverse merger with Chondrial Therapeutics
- Representation of underwriters in connection with public offerings for AC Immune, Edge Therapeutics, Flexion Therapeutics, Freeline Therapeutics, Genfit, InflaRX, Intrexon Corporation, NPS Pharmaceuticals, Ovid Therapeutics, Repare Therapeutics, Reata Pharmaceuticals, Roka Biosciences, Tokai Pharmaceuticals and Regulus Therapeutics
Professional Activities
Mr. Bloom is a member of the American, Massachusetts and Boston Bar Associations.
Professional Experience
Prior to joining Goodwin, Mr. Bloom was a partner at Testa, Hurwitz & Thibeault in Boston, where he was a member of the Business Practice Group and co-chair of its Life Sciences Practice.
